PharmExec Blog

Alliance Management is Being Neglected, Says Study

Survey finds disconnect between perceived importance of alliance management function at  C-level and actual commitment to it.

The Rhythm of Business has released the results of a recent study titled The Practice of Alliance Management in the Biopharmaceutical Industry that examines the state of alliance management in pharmaceutical companies. The study, co-sponsored by the Biopharma Council of the Association of Strategic Alliance Professionals (ASAP), finds that despite nearly unanimous agreement among study participants that alliances and other collaborations are increasingly important to company strategies, alliance professionals report that investment in managing alliances is not keeping pace.
Specifically, the study reveals that while a majority of alliance managers at companies with an established alliance management function believe they are viewed by their CEOs as essential to achieving corporate strategy, they are not being afforded the influence necessary to drive those outcomes. Two-thirds of participants are not satisfied with the influence they presently have and veterans of functions in existence for more than five years are most likely to be unhappy with the sway they have within their organizations. This phenomenon is further crystallized in terms of alliance managers’ perceptions of their growth prospects; over time, alliance managers are less likely to see the position as a path to senior leadership, despite the fact that the role is a sophisticated one, requiring a savvy business person with multi-dimensional talent.
Despite the perceived importance of alliances, companies’ lack of follow-through can be seen in the amount and quality of manpower committed to achieving company objectives through the alliance function—a majority of study participants report five or fewer full-time alliance management professionals, who are most commonly responsible for three or fewer alliances.
In many companies, alliances generate more than half of both revenue and product pipeline. Sixty percent of participants report alliances in their company’s portfolio that are not managed by alliance professionals. However, partnering brings specialized management challenges. The profession of strategic alliance management has developed in response to an historical failure rate in these relationships that exceeds 50 percent because of management-related reasons. ASAP’s biennial State of Alliance Management Study has previously found that dedicated alliance managers and the consistent use of the tools and techniques of the alliance management discipline result in greater likelihood that alliances achieve their strategic objectives.
The risk for biopharmaceutical CEOs is that undermanaged alliance portfolios become underperforming and fail to achieve their revenue and growth objectives.
The Practice of Alliance Management in the Biopharmaceutical Industry aggregates data from 47 biopharmaceutical companies, including half of the top 50 firms by revenue: 56 percent with headquarters in the Americas, 33 percent in Europe, and 11 percent in Asia. The study was heavily weighted towards participation from companies that have a specialized alliance management function in place.
The study examines in detail the role, responsibilities, and organization of the alliance management function in biopharmaceutical companies. Clear differences were found when the data were segregated based on the maturity of the function and its size. Among the findings:
• Alliance management groups take on an increasing array of responsibilities throughout their first five years. After that they relinquish key responsibilities, including planning and evaluation.
• As the alliance portfolio grows, alliance management groups will be required to diversify the alliance management capability with functional managers who have part-time alliance management responsibility.
The study concludes that to realize the strategic and financial objectives of their alliances, companies must take steps to ensure that their alliance and collaboration capability is aligned with the management needs of their alliance portfolio. As portfolios grow larger and increasingly more complex, the risk is that by not investing in the professional management of alliances, they will underperform.
The white paper or executive summary on the results of The Practice of Alliance Management in the Biopharmaceutical Industries may be downloaded at www.rhythmofbusiness.com.

A study examining the state of alliance management in pharmaceutical companies has revealed that, despite nearly unanimous agreement among study participants that alliances and other collaborations are increasingly important to company strategies,  investment in managing alliances is not keeping pace.

The Practice of Alliance Management in the Biopharmaceutical Industry, co-sponsored by the Biopharma Council of the Association of Strategic Alliance Professionals (ASAP) and The Rhythm of Business, found that while a majority of alliance managers at companies with an established alliance management function believe they are viewed by their CEOs as essential to achieving corporate strategy, they are not being afforded the influence necessary to drive those outcomes.

Two-thirds of participants are not satisfied with the influence they presently have and veterans of functions in existence for more than five years are most likely to be unhappy with the sway they have within their organizations. This phenomenon is further crystallized in terms of alliance managers’ perceptions of their growth prospects; over time, alliance managers are less likely to see the position as a path to senior leadership, despite the fact that the role is a sophisticated one, requiring a savvy business person with multi-dimensional talent.

Despite the perceived importance of alliances, companies’ lack of follow-through can be seen in the amount and quality of manpower committed to achieving company objectives through the alliance function—a majority of study participants report five or fewer full-time alliance management professionals, who are most commonly responsible for three or fewer alliances.

In many companies, alliances generate more than half of both revenue and product pipeline. Sixty percent of participants report alliances in their company’s portfolio that are not managed by alliance professionals. The study examines in detail the role, responsibilities, and organization of the alliance management function in biopharmaceutical companies. Clear differences were found when the data were segregated based on the maturity of the function and its size. Among the findings:

• Alliance management groups take on an increasing array of responsibilities throughout their first five years. After that they relinquish key responsibilities, including planning and evaluation.

• As the alliance portfolio grows, alliance management groups will be required to diversify the alliance management capability with functional managers who have part-time alliance management responsibility.

The study concludes that to realize the strategic and financial objectives of their alliances, companies must take steps to ensure that their alliance and collaboration capability is aligned with the management needs of their alliance portfolio. As portfolios grow larger and increasingly more complex, the risk is that by not investing in the professional management of alliances, they will underperform.

The white paper or executive summary on the results of The Practice of Alliance Management in the Biopharmaceutical Industries may be downloaded at www.rhythmofbusiness.com.
This entry was posted in Biotech, leadership, Strategy and tagged , , . Bookmark the permalink. Trackbacks are closed, but you can post a comment.

Post a Comment

Your email is never published nor shared. Required fields are marked *

*
*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

  • Categories

  • Meta